Increased African-American involvement in vaccine studies

Journal of Clinical Epidemiology

Volumn 62, Issue 1, 2009, Pages 111-113

  Ngauy, Viseth ^a   Bautista, Christian T ^a   Duffy, Kathleen ^a   Humphries, M J ^a   Lewis, Yolanda ^a   Marovich, Mary ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; CP205; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT GLYCOPROTEIN GP 120; UNCLASSIFIED DRUG; VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICAN AMERICAN; ANTIBODY RESPONSE; CLINICAL RESEARCH; CLINICAL TRIAL; COMMUNITY; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; HEALTH PROMOTION; HISPANIC; HUMAN; IMMUNOGENICITY; INFORMATION DISSEMINATION; LETTER; MINORITY GROUP; PRIORITY JOURNAL; UNITED STATES;

AFRICAN AMERICANS; ANTHRAX; CLINICAL TRIALS AS TOPIC; DISTRICT OF COLUMBIA; HIV INFECTIONS; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES;

EID: 57449094397     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2008.08.009     Document Type: Letter

References (8)

1. Opar A. New schemes aim to boost minority participation in research. Nat Med 13 (2007) 764-765
2. CDC. HIV/AIDS Surveillance report. Cases of HIV Infection and AIDS in the United States and Dependent Areas, 2006. Accessed Oct 18, 2008. Available at http://www.cdc.gov/hiv/topics/surveillance/resources/reports/index.htm#surveillance.
3. Census Bureau. Annual estimates of the population by sex, race, and Hispanic or Latino origin for the United States: 2006 American Community Survey. Accessed on October 18, 2008. Available at http://factfinder.census.gov.
4. Djomand G., Katzman J., di Tommaso D., Hudgens M.G., Counts G.W., Koblin B.A., et al. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002. Public Health Rep 120 (2005) 543-548
5. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F., and The rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191 (2005) 654-665
6. U.S. Census, 2006 American Community Survey (Accessed on October 18, 2008. Available at http://factfinder.census.gov.
7. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al., Vaccine Research Center 004 Study Team. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194 (2006) 1650-1660
8. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al., Vaccine Research Center 006 Study Team. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194 (2006) 1638-1649